Christina Baik
Fred Hutch/University of Washington Cancer Consortium
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Christina Baik as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:19 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07322341 · SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung CancerUniversity of Washington · recruiting · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma · principal investigator
- Ph2NCT01620190 · Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerUniversity of Washington · completed · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Biostatistics and Data Science CoreP50CA228944 · NCI · FRED HUTCHINSON CANCER CENTER · PI Mary W Redman · fiscal years 2019 to 2026Named on NCT07322341
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2018 to 2026Named on NCT01620190
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:19 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- 2,232 citationsRCR 80.0
- Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.Lancet Oncol · 2016699 citationsRCR 20.7
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.Lancet Oncol · 2021365 citationsRCR 19.2
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.Lancet Diabetes Endocrinol · 2021307 citationsRCR 17.7
- Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.Cancer Discov · 2022270 citationsRCR 17.1
- Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis.J Thorac Oncol · 2022224 citationsRCR 13.7
- Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.Clin Cancer Res · 2019209 citationsRCR 6.9
- 183 citationsRCR 19.1
- 181 citationsRCR 20.1
- 170 citationsRCR 10.9